What is the recommended management of multidrug‑resistant uropathogenic Escherichia coli urinary tract infection?

Management of Multidrug-Resistant UPEC

For multidrug-resistant uropathogenic E. coli urinary tract infections, nitrofurantoin and fosfomycin remain first-line oral options for uncomplicated cystitis due to persistently low resistance rates, while ESBL-producing strains require carbapenems for severe infections or specific oral alternatives based on susceptibility testing. 1, 2

Uncomplicated Cystitis in MDR-UPEC

First-line oral agents that maintain efficacy:

• Nitrofurantoin (5-day course) - resistance remains low even among MDR strains 1, 3
• Fosfomycin tromethamine (3-g single dose) - maintains low resistance rates across MDR populations 1, 3
• Pivmecillinam (5-day course) - effective against many MDR strains including some ESBL-producers 1

Avoid empiric use of these agents due to high resistance:

• Trimethoprim-sulfamethoxazole shows 14.6-60% resistance in European countries and should not be used empirically 3
• Fluoroquinolones (ciprofloxacin, levofloxacin) demonstrate 43.6-47.3% resistance rates, with MDR strains showing nearly universal fluoroquinolone resistance 4

ESBL-Producing UPEC

Oral treatment options for ESBL-E. coli UTIs:

• Nitrofurantoin, fosfomycin, and pivmecillinam remain viable 1
• Amoxicillin-clavulanate can be used for ESBL-E. coli (but NOT for ESBL-Klebsiella) 1
• Newer fluoroquinolones: finafloxacin and sitafloxacin 1

Parenteral options for severe ESBL-UPEC infections:

• Carbapenems are the current mainstay (meropenem/vaborbactam, imipenem/cilastatin-relebactam) 1, 2
• Piperacillin-tazobactam (for ESBL-E. coli only, not other Enterobacterales) 1
• Novel β-lactam combinations: ceftazidime-avibactam, ceftolozane-tazobactam 1, 2
• Cefiderocol 1, 2
• Aminoglycosides including plazomicin 1

Critical caveat: Carbapenem overreliance is driving carbapenem-resistance emergence in UPEC populations, necessitating judicious use and consideration of carbapenem-sparing alternatives when possible 2

Carbapenem-Resistant UPEC

Treatment options for CRE-UPEC:

• Ceftazidime-avibactam 1, 2
• Meropenem/vaborbactam, imipenem/cilastatin-relebactam 1
• Cefiderocol 1, 2
• Aminoglycosides including plazomicin 1
• Fosfomycin (IV formulation) 1, 2
• Polymyxins (colistin) 1, 2
• Tigecycline 1, 2

For metallo-β-lactamase producers (NDM, IMP-4):

• Combination therapy: ceftazidime-avibactam PLUS aztreonam is the preferred approach 2
• Alternative combination: aztreonam plus amoxicillin-clavulanate 1

Clinical Algorithm

Step 1: Determine infection severity and site

• Uncomplicated cystitis → oral agents (nitrofurantoin, fosfomycin, pivmecillinam) 1
• Pyelonephritis or complicated UTI → consider parenteral therapy initially 3

Step 2: Assess resistance risk factors

• Recent antibiotic exposure (especially fluoroquinolones or TMP-SMX) 1
• Previous ESBL or MDR organism isolation 1
• Healthcare-associated infection 4
• Male gender (associated with fluoroquinolone resistance and MDR phenotype) 4

Step 3: Obtain cultures before treatment

• Essential for MDR-UPEC to guide definitive therapy 5
• Adjust therapy based on susceptibility results 1

Step 4: Antimicrobial stewardship

• Reserve carbapenems and novel agents for documented resistant infections to prevent further resistance development 1, 2
• Local antibiograms should guide empiric choices when available 1

Important Pitfalls

• Do not use fluoroquinolones or TMP-SMX empirically in communities with high resistance rates or in patients with recent exposure 1, 3
• Hospital-acquired infections show higher rates of third-generation cephalosporin and nitrofurantoin resistance 4
• Piperacillin-tazobactam only works for ESBL-E. coli, not other ESBL-producing Enterobacterales 1
• Continuous surveillance of local resistance patterns is mandatory to prevent treatment failure 4